Addendum. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2023. Diabetes Care 2023;46(Suppl. 1):S49-S67.
作者信息
ElSayed Nuha A, Aleppo Grazia, Aroda Vanita R, Bannuru Raveendhara R, Brown Florence M, Bruemmer Dennis, Collins Billy S, Cusi Kenneth, Hilliard Marisa E, Isaacs Diana, Johnson Eric L, Kahan Scott, Khunti Kamlesh, Leon Jose, Lyons Sarah K, Perry Mary Lou, Prahalad Priya, Pratley Richard E, Seley Jane Jeffrie, Stanton Robert C, Gabbay Robert A
出版信息
Diabetes Care. 2023 Sep 1;46(9):1718-1720. doi: 10.2337/dc23-ad09.
Abstract
摘要
相似文献
1
Addendum. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2023. Diabetes Care 2023;46(Suppl. 1):S49-S67.附录4. 合并症的综合医学评估与评价：2023年糖尿病护理标准。《糖尿病护理》2023年；46（增刊1）：S49 - S67。
Diabetes Care. 2023 Sep 1;46(9):1718-1720. doi: 10.2337/dc23-ad09.
2
Erratum. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2023. Diabetes Care 2023;46(Suppl. 1):S49-S67.勘误。4. 合并症的综合医学评估与评定：2023年糖尿病照护标准。《糖尿病护理》2023年；46（增刊1）：S49 - S67。
Diabetes Care. 2023 Sep 1;46(9):1722. doi: 10.2337/dc23-er09a.
3
Addendum. 3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Care in Diabetes-2023. Diabetes Care 2023;46(Suppl. 1):S41-S48.附录3. 2型糖尿病及其相关合并症的预防或延缓：2023年糖尿病照护标准。《糖尿病护理》2023年；46（增刊1）：S41 - S48。
Diabetes Care. 2023 Sep 1;46(9):1716-1717. doi: 10.2337/dc23-ad08a.
4
Erratum. Comprehensive Medical Evaluation and Assessment of Comorbidities. Sec. 3. In . Diabetes Care 2017;40(Suppl. 1);S25-S32.勘误。合并症的综合医学评估与评价。第3节。载于《糖尿病护理》2017年；40（增刊1）；S25 - S32。
Diabetes Care. 2017 Jul;40(7):985. doi: 10.2337/dc17-er07. Epub 2017 May 18.
5
Addendum. 7. Diabetes Technology: . Diabetes Care 2020;43(Suppl. 1):S77-S88.附录7.糖尿病技术：《糖尿病护理》2020年；43（增刊1）：S77 - S88。
Diabetes Care. 2020 Aug;43(8):1981. doi: 10.2337/dc20-ad08c. Epub 2020 Jun 5.
6
Addendum. 2. Classification and Diagnosis of Diabetes: . Diabetes Care 2021;44(Suppl. 1):S15-S33.附录2. 糖尿病的分类与诊断：《糖尿病护理》2021年；44（增刊1）：S15 - S33。
Diabetes Care. 2021 Sep;44(9):2182. doi: 10.2337/dc21-ad09. Epub 2021 Jun 16.
7
Addendum. 8. Obesity Management for the Treatment of Type 2 Diabetes: . Diabetes Care 2020;43(Suppl. 1):S89-S97.附录8. 2型糖尿病治疗中的肥胖管理：《糖尿病护理》2020年；43（增刊1）：S89 - S97。
Diabetes Care. 2020 Aug;43(8):1980. doi: 10.2337/dc20-ad08b. Epub 2020 Jun 5.
8
Addendum. 11. Microvascular Complications and Foot Care: : Diabetes Care 2021;44(Suppl. 1):S151-S167.附录11. 微血管并发症与足部护理：《糖尿病护理》2021年；44（增刊1）：S151 - S167。
Diabetes Care. 2021 Sep;44(9):2186-2187. doi: 10.2337/dc21-ad09b. Epub 2021 Jun 16.
9
Addendum. 10. Cardiovascular Disease and Risk Management: . Diabetes Care 2020;43(Suppl. 1):S111-S134.附录。10. 心血管疾病与风险管理：《糖尿病护理》2020年；43（增刊1）：S111 - S134。
Diabetes Care. 2020 Aug;43(8):1977-1978. doi: 10.2337/dc20-ad08. Epub 2020 Jun 5.
10
Addendum. 10. Cardiovascular Disease and Risk Management: . Diabetes Care 2021;44(Suppl. 1):S125-S150.附录。10. 心血管疾病与风险管理：《糖尿病护理》2021年；44（增刊1）：S125 - S150。
Diabetes Care. 2021 Sep;44(9):2183-2185. doi: 10.2337/dc21-ad09a. Epub 2021 Jun 16.
引用本文的文献
1
The Genetic Polymorphisms of rs161620 and rs2229611 in G6PC 3'UTR Are Associated With Metformin Efficacy in Chinese Type 2 Diabetes Mellitus.G6PC 3'UTR区域中rs161620和rs2229611的基因多态性与中国2型糖尿病患者二甲双胍疗效相关。
Pharmacol Res Perspect. 2025 Apr;13(2):e70090. doi: 10.1002/prp2.70090.
2
Regional Difference of Liver Cancer in Japan: A Real-world Evidence Using the National Database of Health Insurance Claims.日本肝癌的地区差异：基于全国医疗保险索赔数据库的真实世界证据
Intern Med. 2025 Aug 1;64(15):2263-2269. doi: 10.2169/internalmedicine.4820-24. Epub 2025 Feb 8.
3
Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Mellitus: A Review and Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association.代谢功能障碍相关脂肪性肝病在 2 型糖尿病中的作用：韩国糖尿病协会脂肪肝研究组的综述和立场声明。
Diabetes Metab J. 2024 Nov;48(6):1015-1028. doi: 10.4093/dmj.2024.0541. Epub 2024 Nov 21.
4
Effects of SGLT2 inhibitors on the onset of esophageal varices and extrahepatic cancer in type 2 diabetic patients with suspected MASLD: a nationwide database study in Japan.SGLT2 抑制剂对疑似 MASLD 的 2 型糖尿病患者食管静脉曲张和肝外癌症发生的影响：日本全国数据库研究。
J Gastroenterol. 2024 Dec;59(12):1120-1132. doi: 10.1007/s00535-024-02158-z. Epub 2024 Oct 11.
5
Metabolic-Associated Fatty Liver Disease and Cognitive Performance in Type 2 Diabetes: Basal Data from the Phytate, Neurodegeneration and Diabetes (PHYND) Study.2型糖尿病中的代谢相关脂肪性肝病与认知表现：来自植酸盐、神经退行性变和糖尿病（PHYND）研究的基础数据。
Biomedicines. 2024 Sep 2;12(9):1993. doi: 10.3390/biomedicines12091993.
6
Nonalcoholic steatohepatitis/metabolic dysfunction-associated steatohepatitis emerging market: Preparing managed care for early intervention, equitable access, and integrating the patient perspective.非酒精性脂肪性肝炎/代谢相关脂肪性肝病新兴市场：为早期干预、公平获得和整合患者视角做好管理式医疗准备。
J Manag Care Spec Pharm. 2024 Sep;30(9-a Suppl):S1-S13. doi: 10.18553/jmcp.2024.30.9-a.s1.
7
Deploying a metabolic dysfunction-associated steatohepatitis consensus care pathway: findings from an educational pilot in three health systems.部署与代谢功能障碍相关的脂肪性肝炎共识护理路径：三项卫生系统教育试点的结果。
BMC Prim Care. 2024 Jul 20;25(1):265. doi: 10.1186/s12875-024-02517-y.
8
Glucokinase regulatory protein rs780094 polymorphism is associated with type 2 diabetes mellitus, dyslipidemia, non-alcoholic fatty liver disease, and nephropathy.葡萄糖激酶调节蛋白rs780094多态性与2型糖尿病、血脂异常、非酒精性脂肪性肝病及肾病相关。
World J Diabetes. 2024 May 15;15(5):814-817. doi: 10.4239/wjd.v15.i5.814.
9
Selective Agonists of Thyroid Hormone Receptor Beta: Promising Tools for the Treatment of Nonalcoholic Fatty Liver Disease.甲状腺激素受体β的选择性激动剂：治疗非酒精性脂肪性肝病的有前景工具。
Endocrinol Metab (Seoul). 2024 Apr;39(2):285-287. doi: 10.3803/EnM.2024.203. Epub 2024 Apr 25.
10
The Potential Role of Presepsin in Predicting Severe Infection in Patients with Diabetic Foot Ulcers.前降钙素原在预测糖尿病足溃疡患者严重感染中的潜在作用。
J Clin Med. 2024 Apr 17;13(8):2311. doi: 10.3390/jcm13082311.
本文引用的文献
1
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.每周一次给予 2.4 毫克司美格鲁肽治疗非酒精性脂肪性肝炎相关肝硬化患者：一项随机、安慰剂对照的 2 期临床试验。
Lancet Gastroenterol Hepatol. 2023 Jun;8(6):511-522. doi: 10.1016/S2468-1253(23)00068-7. Epub 2023 Mar 16.
2
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.美国肝病研究学会非酒精性脂肪性肝病临床评估与管理实践指南
Hepatology. 2023 May 1;77(5):1797-1835. doi: 10.1097/HEP.0000000000000323. Epub 2023 Mar 17.
3
Diabetes and cirrhosis: Current concepts on diagnosis and management.糖尿病与肝硬化：诊断与管理的当前概念
Hepatology. 2023 Jun 1;77(6):2128-2146. doi: 10.1097/HEP.0000000000000263. Epub 2023 Jan 13.
4
Effects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With Cirrhosis.高胆固醇血症和他汀类药物暴露对大型全国肝硬化患者队列生存的影响。
Gastroenterology. 2019 May;156(6):1693-1706.e12. doi: 10.1053/j.gastro.2019.01.026. Epub 2019 Jan 18.
5
Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis.他汀类药物的使用与慢性肝病患者肝硬化及相关并发症风险的关系：系统评价和荟萃分析。
Clin Gastroenterol Hepatol. 2017 Oct;15(10):1521-1530.e8. doi: 10.1016/j.cgh.2017.04.039. Epub 2017 May 4.
6
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.美国临床内分泌医师协会和美国内分泌学会肥胖患者医疗护理综合临床实践指南
Endocr Pract. 2016 Jul;22 Suppl 3:1-203. doi: 10.4158/EP161365.GL. Epub 2016 May 24.
Zotero 插件